APTINYX INC (APTX) Stock News

NASDAQ:APTX - US03836N1037 - Common Stock

0.061 USD

-0.04 (-39%)

Last: 5/18/2023, 8:22:26 PM

0.074 USD

+0.01 (+21.31%)

After Hours: 5/18/2023, 8:22:26 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

APTX Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Benzinga - Mentions: HOOK OMI SNGX BIOL ...

12 Health Care Stocks Moving In Friday's Intraday Session

2 years ago - By: Benzinga - Mentions: ADT ASNS GCI NBTX ...

Why Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

2 years ago - By: Aptinyx Inc.

Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives

2 years ago - By: InvestorPlace - Mentions: ILAG CBIO

Why Is Aptinyx (APTX) Stock Down 64% Today?

2 years ago - By: InvestorPlace - Mentions: DR PEAR TRKA TGL ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

2 years ago - By: InvestorPlace - Mentions: AMC WMT AHCO ILAG

AMC Stock Alert: AMC Entertainment Launches Popcorn Line at Walmart

2 years ago - By: InvestorPlace - Mentions: AHCO ILAG CBIO

Why Is AdaptHealth (AHCO) Stock Down 22% Today?

2 years ago - By: InvestorPlace - Mentions: CBIO ILAG EFTR ADMP ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

2 years ago - By: Seeking Alpha

APTX stock falls as Phase 2 trial for Parkinson's disease and dementia fails (NASDAQ:APTX)

2 years ago - By: Aptinyx Inc.

Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

3 years ago - By: Aptinyx Inc.

Aptinyx to Present at the SVB Securities Global Biopharma Conference

3 years ago - By: Aptinyx Inc.

Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience

3 years ago - By: Aptinyx Inc.

Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

3 years ago - By: Aptinyx Inc.

Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant